SCHEMBL10043740

SCHEMBL10043740

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3nc(C)oc3C)ccc1C)c(=O)n2C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
SYK P43405 1/20 0.43
BACE1 P56817 6/20 0.38
BACE2 Q9Y5Z0 3/20 0.38
POLB P06746 3/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPK14 Q16539 3/20 0.36
ABL1 P00519 2/20 0.36
MAPT P10636 2/20 0.35
LCK P06239 1/20 0.35
MAP2K1 Q02750 1/20 0.35
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDM4E B2RXH2 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043700 0.89 SYK (0.47) RAF1BRAFSYKPOLBALDH1A1
SCHEMBL10043683 0.85 NPC1 (0.46) SYKPOLBALDH1A1MAPTTP53
SCHEMBL10043705 0.84 MAPT (0.54) SYKPOLBALDH1A1MAPK14ABL1
SCHEMBL10043695 0.83 SMN1; SMN2 (0.51) SYKPOLBALDH1A1HSD17B10TP53
SCHEMBL10043697 0.83 SYK (0.43) RAF1BRAFSYKBACE1BACE2
SCHEMBL10043675 0.83 SYK (0.49) RAF1BRAFSYKPOLBMAPK14
SCHEMBL10043663 0.83 SYK (0.51) SYKPOLBALDH1A1MAPK14ABL1
SCHEMBL10043664 0.83 SYK (0.49) SYKPOLBALDH1A1MAPK14ABL1
SCHEMBL10043699 0.83 SYK (0.57) RAF1BRAFSYKPOLBALDH1A1
SCHEMBL10043691 0.82 NPC1 (0.48) RAF1BRAFSYKPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAF1 11/4885BRAF 36/4885SYK 42/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC RAF1 11/4885BRAF 36/4885SYK 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.